Detalhe da pesquisa
1.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838010
2.
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol
; 157(2): 379-385, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32081463
3.
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
J Clin Oncol
; 41(5): 974-979, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608305
4.
Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination.
Cancers (Basel)
; 14(18)2022 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139688
5.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
J Clin Oncol
; 38(26): 2981-2992, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32167863
6.
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Breast
; 54: 286-292, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242755
7.
First-line and maintenance therapy for ovarian cancer: current status and future directions.
Drugs
; 74(8): 879-89, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24848752
8.
Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.
Mol Oncol
; 8(8): 1719-28, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25103625
9.
Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
Expert Rev Anticancer Ther
; 13(2): 123-9, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23406552
10.
Tratamiento multimodal en cáncer de cérvix metastásico con respuesta favorable / Complete response in metastatic cervical cancer after multimodality therapy
Prog. obstet. ginecol. (Ed. impr.)
; 58(9): 417-421, nov. 2015. ilus
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-143481